Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
To develop a new curcumin carrier consisting of murumuru butter nanoparticles (SLN-Cs). A phase-inversion temperature method was used to produce SLN-Cs. The interaction of SLN-Cs with murine colon adenocarcinoma (CT26) cells was analyzed by confocal microscopy. Stable SLN-Cs with a high curcumin-loading capacity were obtained. The SLN-Cs were more toxic to CT26 than free curcumin. Fluorescence microscopy images showed the SLN-Cs to be taken up by CT26 cells . These results indicate that SLN-Cs are suitable carriers of curcumin in aqueous media.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/nnm-2021-0229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Bicyclo[1.1.1]pentane-based Olaparib derivatives as novel PARP inhibitors: A dual-action strategy targeting DNA damage and immune activation.
Bioorg Chem
September 2025
School of Pharmacy, Shandong Second Medical University, Weifang 261053, China. Electronic address:
PARP inhibitors play a crucial role in cancer therapy, with PARP7 emerging as a promising target for immunotherapy by modulating the cGAS-STING pathway. In this study, the piperazine ring of Olaparib was replaced with a bicyclo[1.1.
View Article and Find Full Text PDFThe main limitations of cancer treatment with high doses of recombinant interleukin 2 (IL-2) are high toxicity and the undesired expansion of regulatory T cells. The generation of IL-2 mutated variants (muteins) with changes in the affinity for different chains of the IL-2 receptor (IL-2R) allows selective stimulation of effector cells while overcoming its toxicity. As increasing the IL-2 affinity for the IL-2R beta chain leads to better antitumor effect, we generated a group of these muteins using phage display technology, in a previous work.
View Article and Find Full Text PDFChitosan activates NLRP3 inflammasome and cGAS-STING to suppress cancer progression through hexokinase 2 dissociation and mitochondrial dysfunction.
Theranostics
August 2025
Laboratory of Aging Research and Cancer Drug Target, Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, P. R. China.
Chitosan, a natural polysaccharide with known immunostimulatory potential, has shown promise in cancer therapy. However, its direct role in modulating antitumor immunity and the underlying mechanisms remain unclear. This study aimed to explore how unmodified chitosan influences tumor progression and immune responses through innate immune signaling pathways.
View Article and Find Full Text PDFCascade amplification of therapeutic payloads for cancer immunotherapy.
Commun Biol
August 2025
SunVax mRNA Therapeutics, Inc, Beverly, MA, USA.
Achieving sufficient therapeutic payload delivery remains a significant challenge in gene therapy, particularly for cancer immunotherapy, where payload thresholds are critical for efficacy. To address this, we developed a Cascade Amplification of Therapeutic Payloads (CATP) system, leveraging lipid nanoparticles (LNPs) to co-deliver self-amplifying mRNA (SamRNA) and modified mRNA encoding alphavirus capsids and envelopes. The CATP system initiates a dual-amplification process: SamRNA amplifies therapeutic payloads within transfected cells, while capsid and envelope proteins package SamRNA into defective viral particles to infect neighboring cells, enabling secondary payload amplification.
View Article and Find Full Text PDFDiscovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay.
J Med Chem
August 2025
Jiang Su Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Casitas B-lineage lymphoma-b (Cbl-b), a pivotal negative regulator of TCR signaling, is highly expressed in immune cells. Its inhibition potentiates immune-mediated antitumor effects. Herein, we constructed a potent fluorescent tracer, , based on the Cbl-b peptide inhibitor Utilizing this tracer, we established a fluorescence polarization (FP) assay with enhanced sensitivity, discriminative capacity, and precision for the activity evaluation and high-throughput screening of orthosteric Cbl-b Src homology 2 (SH2) domain inhibitors.
View Article and Find Full Text PDF